Quark

Quark will use Transplant Genomics' test to monitor patient responses to its RNAi-based delayed graft function drug following kidney transplantation.

NEW YORK (GenomeWeb) – Quark Pharmaceuticals this week presented data from a Phase II trial of QPI-1002, an siRNA-based drug for the prevention of delayed graft function (DGF) in kidney transplant patients.

Key RNAi Drugs in the Clinic

Premium

NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.

NEW YORK (GenomeWeb) – Quark Pharmaceuticals this week announced that it has completed a Phase II trial of its siRNA-based drug for the prevention of delayed graft function in kidney transplant patients.

NEW YORK (GenomeWeb) – Quark Pharmaceuticals announced this week that it has dosed the first patient in a Phase IIa study of QPI-1007, its siRNA-based treatment for glaucoma.

Quark Pharmaceuticals and Indian biotech firm Biocon announced this week that they have formed a partnership to develop and market siRNA-based drugs.

Roughly three years after partnering with Quark Pharmaceuticals to develop siRNA-based treatments for fibrotic diseases, Japan’s Nitto Denko has initiated its first clinical trial of an RNAi drug.

While RNAi drug developers continue to pursue major indications such as cancer and hepatitis C, a number of these companies are looking to niche diseases as good opportunities to apply the gene-silencing technology.

Less than three months after it was acquired by its biggest investor, Quark Pharmaceuticals is preparing to begin a pivotal study of its neuroprotectant agent QPI-1007 in the ocular disease non-arteritic anterior ischemic optic neuropathy.

Title: Compositions and Methods for Modulating Ghrelin-Mediated Conditions
Patent Number: 8,309,530
Filed: Feb. 4, 2010
Lead Inventor: Eva Szentirmai, Washington State University

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.